Skip to content
Clinical Trials – home
FinlandBack to Finland

Clinical trials in Kangasala

281 clinical trials in Kangasala, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Kangasala at a glance
281
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

281 trials in Kangasala

Open in trial search

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:VXB-213
  • Sponsor:Sanofi Pasteur Inc.

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Contraception+1

Recruiting

Contraceptive efficacy, safety and tolerability of drospirenone 4 mg (LPRI‑CF113) in healthy women of reproductive age over 13 cycles

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Drospirenone
  • Sponsor:Chemo Research S.L.

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Study on ITI-1284 for Patients with Generalized Anxiety Disorder Who Did Not Respond Well to Previous Treatments

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:ITI-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.